Approval · Notice of Compliance 26939 · 2021
GABAPENTIN: Notice of Compliance 26939
Issued October 29, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26939
- Date
- October 29, 2021
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02432080 | Marketed |
| GABAPENTIN | 02432072 | Marketed |
Medicinal ingredients
- GABAPENTIN 800 MG per TAB
- GABAPENTIN 600 MG per TAB